Diaxonhit in vitro specialty diagnostic sales further increase by 7% at mid-year.

Diaxonhit in vitro specialty diagnostic sales
further increase by 7% at mid-year

• Superior commercial performance compensates end of Allergan collaboration;
• Cash strengthened by successful issuance of convertible bonds for €10 million;
• All resolutions submitted to shareholders' vote were approved.

__________________

Paris, France - July 21, 2014 - Diaxonhit, the leading French provider of specialty diagnostic solutions, announces consolidated mid-year turnover as of June 30, 2014 at €15.9 million, an increase of 2% compared to consolidated turnover of €15.6 million as of June 30, 2013.

Total sales of in vitro diagnostic products recorded by InGen, its commercialization affiliate, for the first semester reached €14.5 million, an increase of 7% compared to sales of €13.6 million recorded at mid-year 2013. This increase more than compensates the reduction in R&D revenues related to the Allergan collaboration, which are halved in 2014, the final year before the end of the collaboration.

« I commend our sales team for its performance during the first semester of 2014. It confirms the relevance of our positioning on the specialty diagnostic market, and enables us to become a pure player in diagnostics without affecting our total turnover that continued to grow. This commercial success combined with the progress of our R&D activities makes us very confident for the future of our group. » said Loïc Maurel, President of Diaxonhit's management board.

During the first half of 2014, Diaxonhit also strengthened its cash by successfully issuing convertible bonds with warrants for a total amount of €10 million.

In parallel, all resolutions that were submitted to Diaxonhit shareholders' vote were approved at the Shareholders Annual Meeting held on June 19, 2014 and at the Extraordinary General Meeting held on July 8, 2014.

Next financial release: 2014 Mid-year results, September 18, 2014

____________________

About Diaxonhit

Diaxonhit (NYSE Alternext, FR0004054427, ALEHT) is a French fully integrated leader in the in vitro diagnostic field, involved from research to commercialization of specialty diagnostic products.

With many partnerships and a strong presence in hospitals, Diaxonhit has an extensive commercialization network. Through its affiliate, InGen, it commercializes and services, mostly under exclusivity agreements, in vitro diagnostic kits and advanced equipment. It operates mainly in the fields of transplantation, infectious diseases and autoimmunity, product quality control and rapid tests, including Tetanus Quick Stick ®, a proprietary product. InGen is the leading supplier in France of HLA tests manufactured by Thermo- Fisher/One Lambda, of which it is the largest distributor worldwide.

The group also owns a diversified portfolio of products in development, including both innovative molecular and non-molecular diagnostics, covering three main specialty areas: transplantation, immuno-infection and cancer.

Diaxonhit headquarters are located in Paris and its affiliate in the Paris region. The Group is listed on NYSE Alternext in Paris and is part of the NYSE Alternext OSEO innovation index.

For more information, please visit: http://www.diaxonhit.com.

Disclaimer

This press release contains elements that are not historical facts including, without limitation, certain statements about future expectations and other forward-looking statements. Such statements are based on management's current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those anticipated.

In addition, Diaxonhit, its shareholders, and its affiliates, directors, officers, advisors and employees have not verified the accuracy of, and make no representations or warranties in relation to, statistical data or predictions contained in this press release that were taken or derived from third party sources or industry publications, and such statistical data and predictions are used in this press release for information purposes only.

Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail.